STOCK TITAN

Bio-Techne Corp - TECH STOCK NEWS

Welcome to our dedicated news page for Bio-Techne (Ticker: TECH), a resource for investors and traders seeking the latest updates and insights on Bio-Techne.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bio-Techne's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bio-Techne's position in the market.

Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) to Present at Investor Healthcare Conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
conferences
-
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ:TECH) announces Asuragen's presentation of new clinical laboratory testing solutions at the upcoming AMP meeting, focusing on cystic fibrosis variant detection, cancer monitoring, and resolving conventionally inaccessible disease-causing genes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.88%
Tags
conferences
-
Rhea-AI Summary
Bio-Techne Corporation reported its financial results for the first quarter ended September 30, 2023. First quarter organic revenue increased by 2% to $276.9 million. GAAP earnings per share (EPS) was $0.31 versus $0.55 one year ago. Adjusted EPS was $0.41 compared to $0.45 one year ago. ExoDx prostate test volume increased 49% and revenue increased 39%. ProteinSimple branded portfolio grew 9% in the quarter and 18% excluding China. Cash flow generated from operations increased to $59.4 million, a 6% increase from the prior year. Kim Kelderman was appointed as CEO effective February 1, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.55%
Tags
News
Rhea-AI Summary
Bio-Techne Corporation (NASDAQ: TECH) has announced a dividend payout of $0.08 per share for the quarter ended September 30, 2023. The dividend will be payable on November 24, 2023, to all common shareholders of record on November 10, 2023. Future cash dividends will be considered on a quarterly basis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.55%
Tags
dividends
-
Rhea-AI Summary
Bio-Techne's brand, Lunaphore, will showcase its technologies at the Society for Immunotherapy of Cancer's Annual Meeting. The presentations will highlight the capabilities of the COMET™ product suite in addressing complex biological questions. The symposia and poster presentations will focus on the optimization of anti-cancer therapy approaches and the mapping of immune and tumoral cells. Lunaphore's scientists will provide live demonstrations of the COMET™ system at the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.69%
Tags
conferences
-
Rhea-AI Summary
Bio-Techne Corporation appoints Kim Kelderman as President and CEO, effective February 1, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.24%
Tags
management
Rhea-AI Summary
Bio-Techne Corporation's Wallingford facility receives ISO 13485:2023 certification for its quality management system, demonstrating commitment to clinical applications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
none
-
Rhea-AI Summary
Bio-Techne Corporation to host conference call on October 31, 2023 to announce first quarter fiscal 2024 financial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.16%
Tags
conferences earnings
-
Rhea-AI Summary
Dr. Jordan Laser of Bio-Techne Corporation receives AMP Meritorious Service Award for his dedication and effort in positioning AMP as a premier molecular diagnostics association.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.67%
Tags
none
Rhea-AI Summary
Bio-Techne Corporation hosted presentations at the CASSS CE Pharm conference, highlighting how their ProteinSimple systems improved therapeutic development workflows. Comparability protocols were developed to transfer methods from iCE3 to Maurice, and MauriceFlex was found to overcome challenges in characterizing charge species. These innovations could revolutionize protein heterogeneity analysis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.07%
Tags
none
Bio-Techne Corp

Nasdaq:TECH

TECH Rankings

TECH Stock Data

10.49B
155.39M
0.97%
100.54%
3.39%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Minneapolis

About TECH

bio-techne (formerly techne corp.), nasdaq: tech, is a global life sciences company providing innovative bioactive tools and resources for the research and clinical diagnostic communities. bio-techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. they aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. with over 275,000 products in its portfolio, bio-techne generated approximately $358 million in net sales in fy 2014 and has over 1,000 employees worldwide.